Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $44.29 Average Target Price from Analysts

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have received an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $43.75.

A number of analysts have commented on the company. Stifel Nicolaus initiated coverage on Eyepoint Pharmaceuticals in a report on Thursday. They set a “buy” rating and a $40.00 price objective for the company. Royal Bank Of Canada lowered their price objective on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Guggenheim reaffirmed a “buy” rating and set a $68.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, April 21st. Finally, Chardan Capital upped their price target on Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st.

Institutional Trading of Eyepoint Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Stempoint Capital LP grew its stake in shares of Eyepoint Pharmaceuticals by 129.1% in the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after acquiring an additional 456,915 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Eyepoint Pharmaceuticals by 22.6% during the first quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock valued at $46,419,000 after purchasing an additional 663,439 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of Eyepoint Pharmaceuticals by 2,158.3% during the first quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock valued at $1,355,000 after purchasing an additional 100,447 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Eyepoint Pharmaceuticals by 58.4% during the first quarter. The Manufacturers Life Insurance Company now owns 36,072 shares of the company’s stock worth $465,000 after purchasing an additional 13,297 shares during the last quarter. Finally, Commodore Capital LP purchased a new position in Eyepoint Pharmaceuticals during the first quarter worth about $36,414,000. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT opened at $13.30 on Thursday. The company has a 50-day moving average price of $13.26 and a 200-day moving average price of $14.24. The stock has a market capitalization of $1.12 billion, a P/E ratio of -3.80 and a beta of 1.73. Eyepoint Pharmaceuticals has a 1 year low of $9.40 and a 1 year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.35 million. As a group, equities research analysts anticipate that Eyepoint Pharmaceuticals will post -3.31 earnings per share for the current fiscal year.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.